PCN26 - Real-World Data on the Epidemiology and Treatment of HR +, HER2-Advanced Breast Cancer in Postmenopausal Patients in Different Regions of Russia for Forming Markov Models of Managment of Patients

Abstract

Listen

Translate article

In Russia, breast cancer (BC) took first place in the structure of cancer incidence and mortality in the female population. Modern therapeutic approaches advanced breast cancer (ABC) can achieve clinically significant regression of symptoms, prolong life and improve its quality. Aim of this study was to conduct clinical and epidemiological analysis of reference postmenopausal patients with hormone- (HR+), HER2-ABC in Russia. Survey of experts from different regions of Russia. The questionnaire included the following questions: the proportion of patients with different types of breast cancer; drugs and modes of their appointment as the first, second and third-line treatment of patients postmenopausal HR+, HER2-ABC; hospitalization rate per year; laboratory and instrumental methods of research, consulting, adverse events with the use of drugs in the treatment of patients and their drug regimes correction. From 13 regions of Russia 7 experts refused to provide information on the questionnaire, which may indicate a reluctance to disclose information on the epidemiology and the tactics of the disease. Data were obtained from the regions - Moscow, Saint Petersburg, Republic of Khakassia, Omsk region, Primorsky Krai, Krasnoyarsk Krai. Share of the growth of new breast cancer patients is 10,5-29,6% (median 13.4%) per year. Number of patients with ABC from patients with breast cancer is 9,2-53% (median-30%). On average, 70% of patients with ABC are in menopause. Number of patients with HR+, ER2-ABC at the end of 2013 amounted to Moscow-1772, St. Petersburg-492, Republic of Khakassia-188, Omsk region-344, Primorsky Krai-358, Krasnoyarsk Krai-3471. The average frequency of hospitalizations in these patients is 6 times a year. Proportion of these patients receiving 3-line therapy differed significantly in Moscow and St. Petersburg, as compared with other regions. Obtained clinical and epidemiological data made it possible to fill in the model of management of patients with breast cancer in particular regions of Russia.